Abstract: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.

Abstract: Topically applied pharmaceutical products comprising (a) an active ingredient, (b) an organogel, and (c) a non-irritating permeation enhancer, are disclosed, along with and methods of use and formulations thereof. The topically applied products and methods are intended to be used to enhance any of the transdermal, subdermal, transmembrane, musculoskeletal, transungual, transonychial, and/or peronychial deliveries of a therapeutically effective amount of an active ingredient to a patient. The invention is particularly directed to topically applied pharmaceutical products for enhancing the delivery of a therapeutically effective amount of an active ingredient to a diseased or infected nail bed, nail matrix, and/or nail plate in the toenails or fingernails of a patient suffering from onychomycosis. The invention is also directed to delivery of an anti-inflammatory agent, preferably of the Cox-2 enzyme inhibitory class, topically to a site of soft tissue injury or discomfort.

Abstract: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition.

Abstract: Compositions and methods for treating a patient with a pharmaceutically active peptide that combines a pharmaceutically active peptide, a permeation enhancer, and a carrier, are disclosed.

Abstract: Compositions and methods for treating a patient with insulin that combines insulin, a permeation enhancer, and a carrier that maintains an acidic pH, are disclosed.

Abstract: A pharmaceutical composition comprising: (A) a continuous liquid phase; (B) liquid droplets dispersed in said continuous phase; (C) a pharmaceutically-active compound; (D) an enhancer as described in U.S. Pat. No. 5,023,252; and (E) a hydrocolloid emulsifying agent; including, for example, a composition in which the liquid phase comprises an aqueous solution of insulin and the liquid droplets comprise a solution of the enhancer and a solvent therefore; and the use of the composition to treat a condition for example diabetes in a patient by applying to the membrane of the patient the composition.

Abstract: Topical alcoholic or aqueous alcoholic gels containing ibuprofen or other NSAIDs, such as, naproxen, in substantially neutral salt form, have enhanced penetration through skin and may provide rapid pain/inflammation relief by including in the formulation 2-n-nonyl-1,3-dioxolane or other hydrocarbyl derivative of 1,3-dioxolane-or 1,3-dioxane or acetal, as skin penetration enhancing compound. The amount of propylene glycol may be varied to adjust the initial flux of the NSAID through the skin, especially for ibuprofen, naproxen, and ketorolac.

Abstract: A composition comprising a pharmaceutical compound, a membrane-permeation enhancer, and a polymeric film-forming agent, including, for example, a hydrocarbon-based liquid nail lacquer comprising a solution of an anti-fungal agent in a pharmaceutically-effective amount, a membrane-compatible permeation enhancer in an amount effective to enhance penetration through a membrane or nail of said anti-fungal agent, a polymeric film-forming agent in an amount effective to form an adherent polymeric film on a membrane or nail, and a solvent for forming said solution; and a method for forming on a membrane or nail of the body an adherent film containing a pharmaceutical compound and permeation enhancer from a solution of the components in which there is used a mixture of solvents, including a solvent which is highly volatile and a solvent of lower volatility.

Abstract: Topical alcoholic or aqueous alcoholic gels containing ibuprofen or other NSAIDs, such as, naproxen, in substantially neutral salt form, have enhanced penetration through skin and may provide rapid pain/inflammation relief by including in the formulation 2-n-nonyl-1,3-dioxolane or other hydrocarbyl derivative of 1,3-dioxolane or 1,3-dioxane or acetal, as skin penetration enhancing compound. The amount of propylene glycol may be varied to adjust the initial flux of the NSAID through the skin, especially for ibuprofen, naproxen, and ketorolac.

Abstract: Topical alcoholic or aqueous alcoholic gels containing testosterone, progesterone, estradiol or other hormones have enhanced penetration through skin by including in the formulation 2-n-nonyl-1,3-dioxolane or other hydrocarbyl derivative of 1,3-dioxolane or 1,3-dioxane or acetal, as skin penetration enhancing compound.

Abstract: A composition for the topical transdermal administration to the penis is based on prostaglandin E.sub.1. The composition is non-irritating and effective for relieving erectile impotence or other penile erectile dysfunction. A penetration enhancing effective amount of a dioxolane, dioxane, or acetal skin penetration enhancing compound in a pharmaceutically acceptable aqueous alcoholic carrier is used to facilitate the penetration of the prostaglandin E.sub.1 active ingredient through the skin. Phentolamine or prazosin may be used in combination with prostaglandin E.sub.1.

Abstract: A stabilized complex comprising a growth hormone and an aromatic aldehyde. Specifically, the complex comprises porcine somatotropin and a substituted benzaldehyde and to a method of providing a prolonged release of the somatotropin and improved feed efficiency in animals.

Abstract: A device for effecting the delayed release of an active ingredient comprises a container and, within, a dispersible unit of ingredient, a removable closure and a electrical control circuit for removal of said closure at a designated time to release the active ingredient. Several assemblies are combined to control the administration of veterinary medicaments to ruminant animals as a specific application of the invention.

Abstract: New anthelmintic compounds, compositions and methods of use are described utilizing 5-cycloalkylthio and oxy-2-carbalkoxyaminobenzimidazole. Methods of preparation involve the reaction of 4-cycloalkylthio- or oxy-o-phenylenediamine with methyl cyanocarbamate in aqueous miscible organic solvents.

Abstract: New anthelmintic compositions and methods of use are described utilizing 5-cycloalkylthio and oxy-2-carbalkoxyaminobenzimidazoles as active ingredients.

Abstract: New methyl benzimidazolecarbamate compounds having a heterocyclic thio or oxy moiety at position 5, useful as anthelmintics are described. Methyl-5-(pyridylthio)- and 5-(pyridylmethylthio)-benzimidazolecarbamates are preferred.

Abstract: Methyl 5-propylthio-2-benzimidazolecarbamate is the active ingredient for methods and compositions affording enhanced activity against gastrointestinal helminths in commercial or pet animals. It is also active against lungworms, cestodes and flukes in animals.